Patent directory · USPTO A61K / A61P
Patents matching “treatment”
2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10881660
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted -
US 10881698
Diagnosis and treatment for respiratory tract diseases
granted -
US 10881653
Tricyclic compounds and their use in the treatment of cancer
granted -
US 10881708
Ang (1-7) derivative oligopeptides for the treatment of pain
granted -
US 10881644
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
granted -
US 10874719
Nucleotide phosphate dissipation as a treatment for vascular disorders
granted -
US 10875885
β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment
granted -
US 10875913
Methods of treatment using activatable anti-EGFR antibodies
granted -
US 10874659
Iloperidone metabolite for use in the treatment of psychiatric disorders
granted -
US 10874609
ß-cyclodextrin-based star-shaped polymer, a preparation method therefor and an integrated unimolecular micelle system for diagnosis and treatment thereof
granted -
US 10876116
Anti-ARID3a treatments for inflammatory disorders
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
US 10870673
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10869846
N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
granted -
US 10869865
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
granted -
US 10870854
Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment
granted -
US 10870855
Use of MIR101 or MIR128 in the treatment of seizure disorders
granted -
US 10870672
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 10864285
Methods for the diagnosis and treatment of Sjögren's syndrome
granted -
US 10864206
Treatment of neurodegenerative conditions by disruption of Rhes
granted -
US 10864152
TRPV3 agonists for the treatment of skin conditions
granted -
US 10857174
Morpholino oligonucleotides useful in cancer treatment
granted -
US 10858323
HDAC inhibitors for the treatment of diabetic peripheral neuropathy
granted -
US 10857225
Smallpox vaccine for cancer treatment
granted